C
Casdin Capital, LLC
+ HoldingAGMB
-4.80%
3M Return
$9.050
-0.205 (-2.27%)At close
Loading chart…
- High
- 9.184
- Open
- 9.150
- VWAP
- 8.93
- Volume
- 52.22K
- Mkt Cap
- —
- Low
- 8.566
- Amount
- 466.53K
- EV/EBITDA, TTM
- 0.00
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
AI analysis of Agomab Therapeutics NV (AGMB)
BuyAgomab Therapeutics is a good buy right now due to its promising clinical developments and strong analyst support. The stock is currently priced at $9.05, with a significant upside potential indicated by analyst targets ranging from $34 to $60. Additionally, the recent Phase 2b trial initiation for its drug Ontunisertib in Crohn's disease positions the company well in a market projected to grow significantly, which is a strong positive catalyst. However, the company is currently facing a negative net income of -11.73 million EUR for Q4 2024, which represents a risk to its financial stability.
Valuation Metrics
The current forward P/E ratio for Agomab Therapeutics NV (AGMB) is 0.00, compared to its 5-year average forward P/E of .
Whales holding AGMB
Events Timeline
News
2.007-24NASDAQ.COMBiotech Stocks Surge with Advanced Biomed Leading Gains
8.506-30NASDAQ.COMUniverse Pharma Acquires Patent Portfolio, Shares Surge
- 9.006-24NASDAQ.COM
AgomAb Initiates Phase 2b Trial for Crohn's Disease Drug Ontunisertib
9.504-24seekingalphaAgomAb Therapeutics Reports Increased Losses for 2025
9.504-24NASDAQ.COMAgomab Reports 2025 Financial Results and Future Milestones
AGMB FAQ — answered by Alphio AI
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics. It operates in the Healthcare sector.
Agomab Therapeutics is a good buy right now due to its promising clinical developments and strong analyst support. The stock is currently priced at $9.05, with a significant upside potential indicated by analyst targets ranging from $34 to $60. Additionally, the recent Phase 2b trial initiation for its drug Ontunisertib in Crohn's disease positions the company well in a market projected to grow significantly, which is a strong positive catalyst. However, the company is currently facing a negative net income of -11.73 million EUR for Q4 2024, which represents a risk to its financial stability.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.